Crohn's News Blog

Weblog – Informação sobre DII

Archive for the ‘Humira’ Category

Humira most favored among biologics for Crohn’s disease and ulcerative colitis

leave a comment »

Health | Crohn’s disease | Humira

Abbott/Eisai’s Humira most favored among biologics for Crohn’s disease and ulcerative colitis, says DR report

US gastroenterologists survey by USA-based advisory firm Decision Resources estimate that (assuming no new data on adverse events emerge) they will treat fewer Crohn’s disease patients with Centocor Ortho Biotech/Merck/Mitsubishi Tanabe’s Remicade (infliximab) by the end of 2010, while the percentage of biologics-treated patients receiving Abbott/Eisai’s Humira (adalimumab) will increase to 36%. Surveyed gastroenterologists also indicate that the percentage of patients treated with a biologic who receive UCB/Otsuka’s Cimzia (certolizumab pegol) will rise from 9% to 12% within the next year.

DR’s new Physician & Payer Forum report, titled The Expanding Biologics Landscape in CD and UC: Clinician and Payer Perspective on the Role of Premium-Priced Biologics in CD and UC Treatment also finds that, on average, surveyed gastroenterologists report prescribing Remicade to 31% of their ulcerative colitis patients.

Caso de morte após ensaio clínico com Humira, Infarmed diz que medicamento esta aprovado desde 2003

leave a comment »

Saúde:

Fármaco usado em ensaio clínico fatal legalizado na Europa em 2003

O medicamento Humira, que segundo o Ministério Público foi mal administrado por um reumatologista que começa a ser julgado dia 27 no Porto, é legal em todo o espaço europeu desde 2003, disse à Lusa fonte do Infarmed.

“Este é um medicamento aprovado pela Agência Europeia do Medicamento (EMA) por procedimento centralizado para toda a União Europeia desde setembro de 2003”, disse fonte da Autoridade Nacional do Medicamento, em resposta a pedidos de esclarecimentos da Agência Lusa.

Humira é a designação comercial de fármaco que contém a substância ativa adalimumab. Questionado sobre as características do fármaco, o Infarmed remeteu a Lusa para o Relatório Público Europeu de Avaliação (www.ema.europa.eu).
Leia o resto deste artigo »

What’s behind Humira’s bullish forecast?

with 2 comments

What’s behind Humira’s bullish forecast?

A report predicting that Humira will become the world’s biggest product in two years’ time generated positive news for the Abbott Labs/Eisai arthritis drug. Several factors are driving the bullish forecast.

While growth is by no means a given, analysts are actually optimistic about the entire class of biologics called TNF inhibitors, which are often used to treat rheumatic diseases, like rheumatoid arthritis (RA), ankylosing spondylitis, Crohn’s disease, psoriasis and ulcerative colitis. According to the forecast, by EvaluatePharma, Humira will become the top-selling anti-TNF—and the world’s biggest product—in 2012 with global sales of $8.3 billion and will retain its top spot until 2016, when sales could exceed $10 billion. Anti-TNF drugs from Pfizer/Amgen (Enbrel) and Johnson & Johnson/Merck (Remicade) will reach the no. 3 and no. 7 spots on the top-10 list, the forecast noted.

Jeffrey Stewart, who heads up Abbott’s US Humira business, summed up the reasons why analysts are keen on these drugs. “The unmet need is great, the therapeutic gain and net value is very significant vs. the standard of care, and a significant number of patients [for whom anti-TNF drugs are indicated] still have not been put on these medications,” said Stewart, who is divisional VP for immunology, in Abbott’s pharmaceutical products division.

Read More…»»What’s behind Humira’s bullish forecast?

,

Powered by ScribeFire.

Written by CarlAn

06/05/2010 at 17:09

Seguir

Get every new post delivered to your Inbox.

%d bloggers like this: